Introduction
Numerous lines of evidence indicate that breast cancer is genetically and epigenetically not just one disease but a diverse group of diseases with diverse clinically relevant biological and phenotypical features. Recent technological advances in molecular profiling have led to the identification of an increasing number of molecular subtypes in breast cancer, each with distinct co-regulated and anti-regulated genes. However, the biology of these molecular subtypes and their underlying genetic drivers may be affected by numerous biological factors, including miRNAs.
miRNAs are a class of small nonprotein-coding genes that regulate the expression of genes post-transcriptionally via sequence-specific interaction with the 3' UTR of target mRNAs, resulting in inhibition of translation and/or mRNA degradation [
1,
2]. A large number of studies have established that miRNAs play essential roles in biological processes, such as development [
3,
4], cell proliferation [
5], apoptosis [
6], stress response, and tumorigenesis [
7,
8]. Aberrant expression levels of miRNAs have been observed in many solid cancers including breast cancer. In breast cancer, the expression levels of several miRNAs are significantly different between normal and cancerous tissues, between breast cancers of different molecular subtypes [
9‐
11] with a different prognosis [
12‐
14], and between breast cancers showing different responses to endocrine therapy [
15,
16]. Despite significant progress in the last few years on miRNA biology, the exact biological functions and the genetic factors driving their expression have been revealed for only a limited number of miRNAs in breast cancer.
Human breast cancer cell lines are excellent experimental models and renewable resources to investigate biological functions of clinically important miRNAs both in
in vitro cultured conditions and
in vivo when raised as xenografts [
6,
17‐
20]. Here, using microarrays we analyzed miRNA expression levels in 51 molecularly well-characterized human breast cancer cell lines. We explored the association of individual miRNA expression levels with intrinsic subtypes and the most common recurrent genetic aberrations. Through this analysis, we provide a catalog of miRNAs in human breast cancer cell lines, which can be used to understand underlying biology of clinically relevant miRNAs and to reveal the genetic factors that may be involved in their regulation.
Materials and methods
Breast cancer cell lines
The cohort of 51 human breast cancer cell lines used in this study is listed in Table
1. The origin of the cell lines has been described elsewhere [
21]. Prior to expression profiling, all cell lines were established to be genetically unique, monoclonal and of correct identity by performing STR profiling using the PowerPlex
® 16 system (Promega, Madison, WI, USA). The PowerPlex
® 16 system included 15 STRs and one gender-discriminating locus (Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Amelogenin, Penta D, CSF1PO, D16S539, D7S820, D13S317, and D5S818).
Table 1
Molecular and biochemical characterization of 51 human breast cancer cell lines
SUM185PE | Luminal | - | - | - | - | - | + | + | - |
MDA-MB-175VII | Luminal | + | - | - | - | - | + | + | - |
BT483 | Luminal | + | - | - | - | - | + | + | - |
T47D | Luminal | + | + | - | + | - | + | + | - |
MDA-MB-415 | Luminal | + | + | - | - | - | + | + | - |
ZR75-1 | Luminal | + | + | - | - | - | + | + | - |
MCF-7 | Luminal | + | + | - | - | - | + | ND | - |
SUM52PE | Luminal | + | - | - | - | - | + | ND | - |
UACC812 | Luminal | + | + | ++ | - | - | + | + | - |
MDA-MB-361 | Luminal | + | + | ++ | - | - | + | + | - |
ZR75-30 | Luminal | + | - | ++ | - | - | + | + | - |
SK-BR-5 | Luminal | - | - | ++ | - | - | + | + | - |
OCUB-F | Luminal | - | - | ++ | - | + | + | + | - |
MPE600 | Luminal | + | - | ++ | - | - | + | + | - |
MDA-MB-134VI | Luminal | + | - | - | - | - | + | + | - |
SUM44PE | Luminal | + | + | - | - | - | + | + | - |
CAMA-1 | Luminal | + | - | - | - | - | + | + | - |
BT474 | Luminal | + | + | ++ | - | - | + | + | - |
MDA-MB-330 | Luminal-ERBB2+ | + | - | ++ | - | - | + | + | - |
HCC1419 | Luminal-ERBB2+ | + | - | ++ | - | - | + | + | - |
HCC202 | Luminal-ERBB2+ | - | - | ++ | - | - | + | + | - |
SUM190PT | Luminal-ERBB2+ | - | - | ++ | - | - | + | + | - |
SUM225CWN | Luminal-ERBB2+ | - | - | ++ | - | - | + | + | - |
UACC893 | Luminal-ERBB2+ | - | - | ++ | + | - | + | + | - |
SK-BR-3 | Luminal-ERBB2+ | - | - | ++ | - | - | + | + | - |
EVSA-T | Luminal-ERBB2+ | - | + | ++ | - | - | + | + | - |
MDA-MB-453 | Luminal-ERBB2+ | - | - | ++ | - | - | + | + | - |
HCC1569 | ER-negative-ERBB2+ | - | - | ++ | + | - | - | - | - |
HCC1954 | ER-negative-ERBB2+ | - | - | ++ | + | + | + | - | - |
HCC1500 | ER-negative-ERBB2+ | + | + | - | - | - | + | + | - |
DU4475 | Other | - | - | - | - | + | - | - | - |
SUM229PE | Basal-like | - | - | - | + | + | + | + | - |
HCC1937 | Basal-like | - | - | - | + | + | + | - | - |
MDA-MB-468 | Basal-like | - | - | - | + | + | + | + | - |
HCC1806 | Basal-like | - | - | - | + | + | + | + | + |
HCC70 | Basal-like | - | - | - | + | + | + | + | - |
HCC1143 | Basal-like | - | - | - | + | + | + | + | - |
BT20 | Basal-like | - | - | - | + | + | + | + | - |
SUM149PT | Basal-like | - | - | - | + | + | + | + | - |
HCC1395 | Basal-like | - | - | - | + | + | - | - | - |
SK-BR-7 | Normal-like/claudin-low | - | - | - | + | - | + | - | - |
Hs578T | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
MDA-MB-231 | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
SUM1315M02 | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
MDA-MB-436 | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
BT549 | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
MDA-MB-157 | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
SUM159PT | Normal-like/claudin-low | - | - | - | + | - | - | - | - |
MDA-MB-435s | Normal-like/claudin-low | - | - | - | - | - | - | - | - |
SUM102PT | Normal-like/claudin-low | ND | ND | ND | ND | ND | ND | ND | ND |
HCC38 | Normal-like/claudin-low | ND | ND | ND | ND | ND | ND | ND | - |
The method involved isolation of the genomic DNA from each breast cancer cell line using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and 10 ng of the isolated DNA was used as the input for the multiplex PCR. The following PCR conditions were used: 95°C for 11 minutes, 96°C for 1 minute, 10×(94°C for 30 seconds, 60°C for 30 seconds, 70°C for 45 seconds), 22×(90°C for 30 seconds, 60°C for 30 seconds, 70°C for 45 seconds), and then 60°C for 30 minutes. The PCR was carried out using primers linked with fluorescent dyes (6-carboxy-4',5'-dichloro-2',7'-dimethoxy-fluorescein, fluorescein, and carboxy-tetramethylrhodamine). The labeled amplicons were detected using the 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and data were analyzed using the Genemarker 1.91 software from Softgenetics (State College, PA, USA).
The end result for each cell line was an electropherogram with each STR allele represented as one or more peaks of an appropriate fluorophore. The authenticity of all cell lines, except SUM cell lines, were assessed by comparing the generated STR profiles with the source STR profiles present in the American Type Culture Collection and the Deutsche Sammlung von Mikroorganismen und Zellkulturen. As no reference is available, the STR profiles of the SUM cell lines were matched with the profiles generated from the earliest passage of these cell lines stored in the in-house culture collection.
For experiments, each cell line was cultured in triplicate on collagen-coated petri dishes in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotic agents (100 μg/ml penicillin G and 80 μg/m streptomycin). The petri dishes were placed in a humidified atmosphere of 5% CO2 and 95% air at 37°C until cultures were 70 to 80% confluent. Ethical approval of our study was not necessary as our experiment involved only in vitro propagated human breast cancer cell lines.
Total RNA isolation
Total RNA from all samples was isolated using RNAzol-B reagent (Campro Scientific BV, Veenendaal, the Netherlands) according to the manufacturer's manual. Briefly, a biological sample was lysed in RNAzol-B reagent and the lysate was separated into an aqueous phase and an organic phase after the addition of chloroform. DNA and protein were subsequently removed by carefully transferring the aqueous phase containing RNA to a fresh Eppendorf tube. The RNA was obtained from the aqueous phase by an isopropanol precipitation, washed with ethanol and air dried for subsequent procedures. The purity of the isolated RNA was checked using NanoDrop
® ND-1000 (Isogen Life Science, De Meern, the Netherlands) ensuring spectrophotometric ratios of A
260 nm/A
280 nm ~2 and A
260 nm/A
230 nm ≥ 2, and the quality control checks were performed according to the previously described methodology [
22].
Gene expression profiling
Total RNA (200 ng) was reverse transcribed, copied into double-strand cDNA and labeled to yield biotin-labeled cRNA using the 3' IVT express Kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. Biotin-labeled cRNA was subsequently fragmented and loaded onto an Affymetrix GeneTitan instrument. The hybridization cocktail was applied to Human Genome HT_HG-U133_Plus_PM GeneChip 96-well arrays. All steps including hybridization, washing and scanning were carried out automatically inside the instrument. The raw data (.CEL files) were normalized by the RMA method using the default settings of the Affymetrix Expression Console™ software and were used for statistical analysis. The microarray data were deposited in the Gene Expression Omnibus data repository [GEO:GSE41313].
For subtype classification of the cell lines, Perou and colleagues' intrinsic gene set of 496 genes [
23] were matched to the Affymetrix probe sets using Unigene cluster numbers. Some of the genes have multiple probe sets present. To ensure analysis of only the informative probe sets, the probe sets that did not vary across all samples were removed, leaving the most variable ones for analysis (66% of the probe sets). These genes were then used to cluster the breast cancer cell lines. The intrinsic molecular subtypes were assigned as follows: luminal-type cell lines that exhibited higher expression of
ESR1, GATA3, TFF3, and
FOXA1; ERBB2-positive cell lines that showed higher expression of
ERBB2, GRB7, and
STARD3; basal-like cell lines, which were characterized by higher expression of
KRT5, KRT17, BST2, and
FABP7; and normal-like/claudin-low cell lines that did not show
KRT5 and
KRT17 expression and have low expression of claudin 3, claudin 4, and claudin 7 genes. The ERBB2-positive cell lines were further designated as luminal-ERBB2-positive and estrogen receptor (ER)-negative/ERBB2-positive cell lines, because the former in addition to
ERBB2 overexpression also show
ESR1 gene expression on microarray while the latter do not.
miRNA expression analysis
miRNA expression profiling was performed using miRNA microarrays according to a previously published method [
24]. In brief, 1 μg total RNA was labeled with Cy3 using the ULS aRNA labeling kit (Kreatech, Amsterdam, the Netherlands). The LNA™ modified oligonucleotide capture probe set (miRBase version 10.0, annotation version 13; Exiqon, Vedbaek, Denmark) was spotted in duplicate on Nexterion E glass slides in Nexterion Spot buffer (Schott, Elmsford, NY, USA) using a Virtek Chipwriter Pro (Bio-Rad, Hercules, CA, USA). The RNA sample with a labeling efficiency > 15 pmol Cy3/μg RNA was used for hybridization in a salt-based hybridization buffer (Ocimum Biosolutions, Hyderabad, India) overnight at 60°C using a Tecan HS4800 pro hybridization station. Hybridized slides were scanned in a Tecan LS Reloaded scanner. Data were extracted using Imagene software (6.0 standard edition; TCAN, Chapel Hill, NC, USA). The raw data were normalized using quantile normalization and used for statistical analysis. The normalized expression data are provided in Table S1 in Additional file
1. To validate our findings, subsets of the differentially expressed miRNAs between two miRNA-driven clusters were quantified using the Taqman Human MicroRNA Assay Set from Applied Biosystems (Nieuwerkerk aan den IJssel, the Netherlands) as described previously [
12].
SNP arrays
Genomic DNA from all cell lines was extracted using the QIAamp DNA Mini Kit (Qiagen). Genomic DNA (500 ng) was used as the starting material to capture genome-wide chromosomal aberrations with the aid of the Affymetrix Genome-Wide Human SNP 6.0 array technology. The steps were performed according to Affymetrix's recommended protocols. In summary, after digestion of the genomic DNA using either restriction enzymes NspI or StyI, adaptors were ligated to the obtained DNA fragments. These fragments were subsequently amplified using PCR, fragmented, end-labeled with biotin and hybridized onto GeneChip SNP 6.0 arrays. After hybridization the arrays were washed and scanned to generate the raw data (.CEL files) using the Affymetrix Genotyping Console™ software. The chromosomal gains and losses were calculated using SNP copy number variation (CNV) on the same chromosome. The chromosomal regions containing gains or losses were correlated with the expression level of the miRNAs located on the same genomic regions. The SNP data were deposited in the GEO data repository [GEO:GSE41313].
Protein expression and mutational analysis
Protein expression data of ER, progesterone receptor, ERBB2, epidermal growth factor receptor, and cytokeratin (CK) 5, CK8-18, CK19, and CK14 were used from previously published work [
25], except for 10 HCC cell lines that were characterized by immunohistochemistry using the same protocols as described before [
25]. Mutational analysis of
p16
INK4a
, BRCA1, E-cadherin, PIK3CA, and
PTEN and promoter hypermethylation analysis of
E-cadherin were previously reported for all cell lines except for HCC cell lines. These were separately analyzed according to the previously published methods [
25] (data presented in Table S2 in Additional file
1).
Hierarchical clustering and statistical analyses
Hierarchical clustering analyses of significant miRNAs were performed using Cluster 3 software [
26] and the expression patterns of miRNAs and mRNAs in the heat maps were visualized using Treeview 1.1.6 R2. Average linkage clustering was carried out on both samples and mRNA and miRNA expression data, respectively, using Pearson correlation as a distance measure. Differential expression of miRNAs between two groups was determined using the univariate
t test in BRB-array tools 3.7 developed by Dr. Richard Simon and the BRB-ArrayTools Development Team). A permutation value of
P < 0.05 was considered statistically significant and used to select differentially expressed miRNAs for supervised hierarchical cluster analysis. The associations between continuous variables were tested using Spearman Rank correlation (
Rs values). The Kruskal-Wallis test was used to evaluate differences among groups and
P < 0.05 was considered statistically significant.
Discussion
Human breast cancer cell lines are renewable resources that are extensively utilized as reliable workhorses to explore biological functions of clinically relevant molecules in breast cancer. Extensive molecular characterization and gene mutation analysis by us and other researchers have suggested that breast cancer cell lines have retained significant molecular features that are commonly observed in clinical breast tumors [
36,
37]. This suggestion prompted us to use 51 human breast cancer cell lines as a discovery cohort to identify differentially expressed miRNAs between known intrinsic subtypes of breast cancer as well as those associated with common genetic aberrations present in the cell lines.
In this study, we demonstrated that global miRNA expression profiling can assign our cell line collection into two clusters. These two clusters predominantly mirror the ER-based dichotomy present in human breast cancer cell lines, which may point to the fact that, like mRNA, miRNA expression profiling allows the discrimination between ER-positive and ER-negative cell lines. This suggests that a significant number of miRNAs may be under the control of ER regulation. In line with this, we observed a trend of finding ER binding sites closer to the significantly differentially expressed miRNAs between ER-positive and ER-negative cell lines than nonsignificant miRNAs (see Table S19 in Additional file
1 and Figure S4 in Additional file
2). Interestingly, not all miRNAs discriminating ER-positive and ER-negative cell lines are associated with ER status and therefore the division of the cell lines into two clusters may not be purely dictated by the expression of ER-related miRNAs, but these miRNAs are probably also related to luminal versus basal cellular differentiation.
Our supervised analysis revealed a signature of 79 differentially expressed miRNAs between ER-positive and ER-negative cell lines. Six of these miRNAs were also found similarly differentially expressed between ER-positive and ER-negative primary tumor specimens as they were in cell lines [
29] (see Table S4B in Additional file
1). This overlap may seem small but we have observed discrepancies between miRNA profiling platforms (unpublished observations), and our study used LNA™ technology-based microarrays to quantify miRNA expression in the cell lines whereas Cimino and colleagues used Agilent microarrays to measure miRNAs in tumors. Also not all miRNAs are present on both platforms, which already explains one-half of the discrepancies. Furthermore, tumor heterogeneity and stromal contribution (such as connective tissues, blood vessels and immune infiltrates) and a likely selection bias in the cell lines - which are more ER-negative, mesenchymal, and
TP53 mutant than primary tumors - could explain the observed discrepancies. A perfect correlation would thus not have been anticipated. Reassuringly, however, we found miRNAs previously reported to be ER-regulated miRNAs, such as a cluster of
hsa-miR-221/222 [
12,
38]. In line with this, we also found a significant inverse correlation between the expression levels of these ER-regulated miRNAs and mRNA expression levels of their functionally validated target genes - for instance,
hsa-miR-221and
hsa-miR-222 have been shown to target the
CDKN1B and
ESR1genes (see Table S20 in Additional file
1). Such miRNAs have been shown to interact directly with ER and cause a phenotypic shift from ER-positive to ER-negative tumor cells [
38]. Our miRNA analyses in this cohort of cell lines therefore confirms previous findings but also revealed new miRNAs (discussed below), which may have potentially interesting biological roles in ER-driven cancer.
Among these potentially novel ER-related miRNAs, four miRNAs (
hsa-miR-26a, hsa-miR-92b, hsa-miR-191, hsa-miR-492) appear to show consistently higher expression across all the ER-positive cell lines (fold change ≥ 1.5), and as yet only
hsa-miR-26a has been implicated in breast carcinogenesis whereas
hsa-miR-26a and
hsa-miR-92b have also been implicated in brain tumors [
39,
40]. In breast cancer, high expression of the
hsa-miR-26a miRNA downregulates
EZH2 and is therefore related to a favorable outcome on tamoxifen in metastatic breast cancer [
41], and also interacts with
CDK4 and
CENTG1 oncogenes and forms an integrated oncomir/oncogene DNA cluster, which promotes glioblastoma tumor growth via RB1, PI3K/AKT, and JNK pathways [
39]. On the other hand,
hsa-miR-92b has been found to be exclusively overexpressed in primary brain tumors but serves as a biomarker to discriminate brain primary cancer from metastasis [
40]. The other two miRNAs (
hsa-miR-191, hsa-miR-492) have been linked to hepatic cancer. The increased expression of
hsa-miR-191 stimulates proliferation in hepatocellular carcinoma cell lines and its therapeutic targeting suppresses tumor masses
in vivo [
42]. The
hsa-miR-492 miRNA has been shown to be processed from the
keratin 19 gene and upregulated in metastatic hepatoblastoma [
43]. How these miRNAs play their biological roles in the context of breast cancer remains unknown and demands clinical and functional validation studies.
Another major contribution to the overall miRNA profiling of this cell line cohort is the identification of a signature of 42 differentially expressed miRNAs, which discriminates between basal-like and normal-like/claudin-low breast cancer cell lines. These miRNAs together with the ER-associated miRNAs are the major determinants of the overall clustering of the cell lines. Importantly, this signature includes all four members of the
hsa-miR-200 family (
hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-141),
hsa-miR-155, and
hsa-miR-622 miRNAs. Several studies have implicated these miRNAs to be involved in epithelial-mesenchymal transition (EMT), to be related to the stem-cell-like phenotype, and to be associated with a switch in paclitaxel responsiveness [
44‐
47]. In breast cancer, these miRNAs are known to regulate the EMT process by targeting the ZEB family of the transcription factors through an active negative feedback loop [
48,
49]. Importantly, the ZEB family of transcription factors was reported to be a repressor of E-cadherin expression in several epithelial carcinomas including breast carcinoma.
Interestingly, we observed a significant inverse correlation between the expression levels of all miRNAs of the
hsa-miR-200 family and the mRNA expression level of the ZEB1 transcription factor, which is a well-known target of this miRNA family (see Table S20 in Additional file
1). Additionally, our finding that the
hsa-miR-200 cluster showed lower expression in normal-like/claudin-low breast cancer cell lines fits with the fundamental literature that these miRNAs are indeed involved in EMT, because the majority of the normal-like/claudin-low cell lines lack E-cadherin protein expression, exhibit low claudin expression, and generally display EMT-like features as well as the breast cancer stem cell phenotype (CD44
high/CD24
low) [
50‐
53]. Other known significant miRNAs of this signature are
hsa-miR-155 and
hsa-miR-622, which were also linked to enhanced tumorigenesis in various cancer types besides breast cancer [
54,
55]. In concordance with this, we recently found that the normal-like/claudin-low cell lines with low expression of these EMT-related miRNAs show highly aggressive growth characteristics
in vivo when raised as xenografts in nude mice (M Riaz and colleagues, unpublished data). Importantly, this signature includes three previously unknown miRNAs (
hsa-miR-492, hsa-miR-26b, hsa-miR-617; fold change ≥ 1.5) found to be associated with cell lines frequently showing EMT-like characteristics.
We observed that the miRNA signatures associated with E-cadherin mutation and promoter hypermethylation include distinct miRNAs. This may point to an existence of unique biology at the miRNA level in tumors that show E-cadherin inactivation due to gene mutation rather than those that lose E-cadherin expression due to promoter hypermethylation. Important to note is that E-cadherin promoter hypermethylated cell lines include all normal-like/claudin-low cell lines, and most EMT-related miRNAs were also associated with E-cadherin promoter hypermethylation.
With respect to common genetic aberrations present in breast cancer, our study reveals differentially expressed miRNA signatures associated with commonly mutated tumor suppressors and oncogenes. Most significantly, a signature of 30 miRNAs associated with
p16
INK4a
mutant cell lines can strongly discriminate between mutant and wild-type ER-negative cell lines.
P16
INK4a
is a tumor suppressor gene located on chromosomal band 9p21 that has been frequently altered in many human cancers [
56].
P16
INK4a
regulates cell cycle progression by targeting CDK4/6 through the pRb signaling pathway. Interestingly, this signature includes some miRNAs that are involved in cell cycle regulation. For instance,
hsa-miR-100, which is highly expressed in the
p16
INK4a
wild-type cell lines, targets the
RBSP3 gene that in acute myeloid leukemia regulates the cell cycle through partial modulation of pRB/E2F1 [
57].
hsa-miR-34a has been reported as a suppressor of cell proliferation and migration in colon cancer [
58] and its mechanism of growth inhibition also involves cell cycle arrest followed by apoptosis [
59]. Besides this, we found a few miRNAs to be only associated with mutation in
BRCA1, TP53 and
PIK3CA/PTEN; these observed associations require further independent validation in breast cancer specimens.
Our finding that the differential expression of miRNAs is associated with ERBB2-overexpressing luminal-type cell lines is also intriguing since the miRNAs showing elevated expression in ERBB2-positive cell lines (fold change ≥ 1.5) are not located on the ERBB2 amplicon (17q12) and thus may be regulated indirectly by genes in the ERBB2 amplicon. It is also important to mention that a majority of these miRNAs have already been implicated in various types of epithelial carcinoma including breast cancer [
60‐
64]. One should, however, note that our study is associative and does not necessarily reveal causality. We therefore propose functional studies on these miRNAs to reveal more biological insights into their role regarding ERBB2 overexpression in breast cancer.
Finally, we also identified 12 miRNAs to be associated with CNVs in breast cancer cell lines (see Table S17 in Additional file
1). The majority of these miRNAs (
hsa-miR-130a, hsa-miR-93, hsa-miR-383, hsa-miR29c, hsa-miR-382, hsa-miR-31) were already found to be located in regions that exhibited DNA copy number abnormalities in breast cancer tumors [
65]. Importantly, this repertoire of miRNAs includes
hsa-miR-22 previously shown to be regulated by ER [
66] and we provide evidence that it can also be regulated by the loss of the locus containing this miRNA. Six miRNAs of this repertoire are located in the genomic regions containing known protein coding genes. All miRNAs of this repertoire have also been implicated in various cancers but a thorough validation of these miRNAs with respect to DNA copy number changes in clinical specimen is imperative.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JAF, JWMM, EAW, and MR designed the study. MR, JAF and JWMM wrote the manuscript. MTMvJ and AWMB performed the miRNA expression analysis. JL and AH performed gene mutation analysis. JH performed STR analysis. BO and WJCP-vdS carried out RNA isolation and quantification. AAJH, MS, and MR performed the statistical data analyses. All authors approved the final version of the manuscript.